SPECIAL REPORT
An important advance in the treatment of migraine has been the development of agents that target calcitonin gene-related peptide (CGRP), a neuropeptide that has emerged as a key player in the neurobiology of migraine. Read More
Latest News
Marijuana in neurology – POTential benefit?
March 23, 2018The Cannabis Act was introduced to the Canadian House of Commons one year ago, which would legalize the possession and use of marijuana. The Act is expected to become law in July 2018. The medical use of marijuana was the thin edge of the legalization wedge, and the new law is likely to fuel even greater interest in marijuana among patients. Read More
MS therapeutics: 1 withdrawal, 1 setback
March 5, 2018Daclizumab (Zinbryta), the anti-CD25 monoclonal antibody approved for the treatment of relapsing MS in May 2016 (December 2016 in Canada), has been voluntarily withdrawn by its manufacturers and will no longer be available. The withdrawal was announced on March 2, in a press release issued by Biogen and AbbVie (www.businesswire.com/news/home/20180302005168/en/Biogen%C2%A0and-AbbVie-Announce%C2%A0the-Voluntary%C2%A0Worldwide-Withdrawal-Marketing-Authorizations). Read More
DMF: the Canadian MS patient experience
February 28, 2018A majority of MS patients currently treated with dimethyl fumarate (DMF) state that their therapy is as easily tolerated as other disease-modifying therapies, according to the results of a recent online survey. The survey was conducted in December 2017-February 2018 on MSology, the sister site of NeuroSens. MSology provides news and resources to MS patients, and attracts about 35,000 visitors per year (www.msology.com). Read More